The NATO project: nanoparticle-based countermeasures for microgravity-induced osteoporosis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 11 2019
Historique:
received: 27 08 2019
accepted: 23 10 2019
entrez: 22 11 2019
pubmed: 22 11 2019
medline: 4 11 2020
Statut: epublish

Résumé

Recent advances in nanotechnology applied to medicine and regenerative medicine have an enormous and unexploited potential for future space and terrestrial medical applications. The Nanoparticles and Osteoporosis (NATO) project aimed to develop innovative countermeasures for secondary osteoporosis affecting astronauts after prolonged periods in space microgravity. Calcium- and Strontium-containing hydroxyapatite nanoparticles (nCa-HAP and nSr-HAP, respectively) were previously developed and chemically characterized. This study constitutes the first investigation of the effect of the exogenous addition of nCa-HAP and nSr-HAP on bone remodeling in gravity (1 g), Random Positioning Machine (RPM) and onboard International Space Station (ISS) using human bone marrow mesenchymal stem cells (hBMMSCs). In 1 g conditions, nSr-HAP accelerated and improved the commitment of cells to differentiate towards osteoblasts, as shown by the augmented alkaline phosphatase (ALP) activity and the up-regulation of the expression of bone marker genes, supporting the increased extracellular bone matrix deposition and mineralization. The nSr-HAP treatment exerted a protective effect on the microgravity-induced reduction of ALP activity in RPM samples, and a promoting effect on the deposition of hydroxyapatite crystals in either ISS or 1 g samples. The results indicate the exogenous addition of nSr-HAP could be potentially used to deliver Sr to bone tissue and promote its regeneration, as component of bone substitute synthetic materials and additive for pharmaceutical preparation or food supplementary for systemic distribution.

Identifiants

pubmed: 31748575
doi: 10.1038/s41598-019-53481-y
pii: 10.1038/s41598-019-53481-y
pmc: PMC6868153
doi:

Substances chimiques

Durapatite 91D9GV0Z28
Alkaline Phosphatase EC 3.1.3.1
Calcium SY7Q814VUP
Strontium YZS2RPE8LE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17141

Références

Biomaterials. 2013 Apr;34(12):2947-59
pubmed: 23375393
J Bone Miner Res. 1993 Dec;8(12):1499-506
pubmed: 8304052
J Cell Physiol. 2007 Apr;211(1):121-30
pubmed: 17187344
Nanomedicine (Lond). 2018 Nov;13(22):2821-2833
pubmed: 30334476
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:653-662
pubmed: 27987756
Nanoscale. 2018 May 10;10(18):8689-8703
pubmed: 29701213
Nat Rev Genet. 2019 Nov;20(11):631-656
pubmed: 31341269
J Biomed Mater Res B Appl Biomater. 2006 May;77(2):409-15
pubmed: 16278857
Bone. 1997 Jun;20(6):547-51
pubmed: 9177869
FASEB J. 2009 Aug;23(8):2549-54
pubmed: 19329761
Lancet. 2000 May 6;355(9215):1607-11
pubmed: 10821365
Adv Drug Deliv Rev. 2016 Dec 15;107:247-276
pubmed: 27125191
Joint Bone Spine. 2011 Dec;78(6):572-6
pubmed: 21664854
Science. 2000 Sep 1;289(5484):1508-14
pubmed: 10968781
Osteoporos Int. 2015 Jun;26(6):1667-71
pubmed: 25868510
Am Fam Physician. 2001 Mar 1;63(5):897-904, 908
pubmed: 11261866
Mater Sci Eng C Mater Biol Appl. 2013 Apr 1;33(3):1132-42
pubmed: 23827552
Bone. 2016 Jun;87:44-56
pubmed: 27032715
J Mater Sci Mater Med. 2015 Feb;26(2):90
pubmed: 25649515
J Bone Miner Res. 2006 Aug;21(8):1224-30
pubmed: 16869720
Nanoscale. 2017 Nov 16;9(44):17274-17283
pubmed: 29090300
Biomed Res Int. 2014;2014:928507
pubmed: 25110709
Nanomaterials (Basel). 2016 Jun 24;6(7):
pubmed: 28335251
J Bone Miner Res. 1994 Apr;9(4):487-96
pubmed: 7518179
Clin Oral Implants Res. 2016 Dec;27(12):e206-e214
pubmed: 25916272
J Clin Invest. 2005 Dec;115(12):3318-25
pubmed: 16322775
Bone. 2001 Apr;28(4):446-53
pubmed: 11336927
Acta Biomater. 2015 Sep;23:309-316
pubmed: 26049151
Biotechnol Bioeng. 2014 Jun;111(6):1180-90
pubmed: 24375199
Tissue Eng Part A. 2010 Mar;16(3):995-1008
pubmed: 19839719
Int J Mol Sci. 2018 Oct 17;19(10):
pubmed: 30336625
J Biomed Mater Res A. 2009 Jun;89(3):594-600
pubmed: 18437694
Osteoporos Int. 2003;14 Suppl 3:S9-12
pubmed: 12730801
Cell. 1997 May 30;89(5):755-64
pubmed: 9182763
Cell Prolif. 2019 Mar;52(2):e12539
pubmed: 30397970
Biomaterials. 2010 May;31(14):3949-56
pubmed: 20170952
PLoS One. 2018 Jun 14;13(6):e0199046
pubmed: 29902240

Auteurs

F Cristofaro (F)

Molecular Medicine Department (DMM), Center for Health Technologies (CHT), UdR INSTM, University of Pavia, Viale Taramelli 3/B, 27100, Pavia, Italy.
Department of Occupational Medicine, Toxicology and Environmental Risks, Istituti Clinici Scientifici Maugeri S.p.A, IRCCS, Via S. Boezio, 28, 27100, Pavia, Italy.

G Pani (G)

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, via D. Trentacoste 2, 20134, Milano, Italy.

B Pascucci (B)

Institute of Crystallography - CNR, via Salaria Km 29.300, 00015, Monterotondo Roma, Italy.

A Mariani (A)

Kayser Italia, S.r.l., Via di Popogna, 501, 57128, Livorno, Italy.

M Balsamo (M)

Kayser Italia, S.r.l., Via di Popogna, 501, 57128, Livorno, Italy.

A Donati (A)

Kayser Italia, S.r.l., Via di Popogna, 501, 57128, Livorno, Italy.

G Mascetti (G)

Italian Space Agency, ASI, Via del Politecnico, 00133, Roma, Italy.

G Rea (G)

Institute of Crystallography - CNR, via Salaria Km 29.300, 00015, Monterotondo Roma, Italy. giuseppina.rea@ic.cnr.it.

A M Rizzo (AM)

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, via D. Trentacoste 2, 20134, Milano, Italy. angelamaria.rizzo@unimi.it.

L Visai (L)

Molecular Medicine Department (DMM), Center for Health Technologies (CHT), UdR INSTM, University of Pavia, Viale Taramelli 3/B, 27100, Pavia, Italy. livia.visai@unipv.it.
Department of Occupational Medicine, Toxicology and Environmental Risks, Istituti Clinici Scientifici Maugeri S.p.A, IRCCS, Via S. Boezio, 28, 27100, Pavia, Italy. livia.visai@unipv.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH